Invasive Haemophilus influenzae type b disease in England and Wales: Who is at risk after 2 decades of routine childhood vaccination?

Clinical Infectious Diseases

Volumn 57, Issue 12, 2013, Pages 1715-1721

  Collins, Sarah ^a   Ramsay, Mary ^a   Campbell, Helen ^a   Slack, Mary P E ^a   Ladhani, Shamez N ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

epidemiology; epiglottitis; Haemophilus influenzae serotype b; outcome; pneumonia

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ADOLESCENT; ARTICLE; BACTEREMIA; CHILD; EPIGLOTTITIS; FATALITY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS INFLUENZAE TYPE B INFECTION; HAEMOPHILUS MENINGITIS; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; NONHUMAN; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED KINGDOM; VACCINATION;

EPIDEMIOLOGY; EPIGLOTTITIS; HAEMOPHILUS INFLUENZAE SEROTYPE B; OUTCOME; PNEUMONIA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MIDDLE AGED; PUBLIC HEALTH SURVEILLANCE; WALES; YOUNG ADULT;

EID: 84890047355     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit579     Document Type: Article

References (29)

1. Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ 1996; 312:160-1
2. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012; 34:385-99
3. Slack MP, Azzopardi HJ, Hargreaves RM, Ramsay ME. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: Impact of conjugate vaccines. Pediatr Infect Dis J 1998; 17: S204-7
4. McVernon J, Howard AJ, Slack MP, Ramsay ME. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 2004; 132:765-7
5. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86:396-9
6. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993; 69:225-8
7. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334-40
8. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8: 435-43
9. Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay ME. Invasive Haemophilus influenzae disease, Europe, 1996-2006. Emerg Infect Dis 2010; 16:455-63
10. MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease; United States, 1989-2008. Clin Infect Dis 2011; 53:1230-6
11. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England andWales: Surveillance study. BMJ 2004; 329:655-8
12. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93:665-9
13. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5
14. Health Protection Agency. Laboratory reports of Haemophilus influenzae by age group and serotype, England and Wales: fourth quarter, and quarters 1-4 inclusive, 2009. Available at: Http://www.hpa.org.uk/hpr/ archives/2010/hpr0810. pdf. Accessed 26 February 2010
15. Ladhani S, Slack MP, Heath PT, Ramsay ME. Changes in ascertainment of Hib and its influence on the estimation of disease incidence in the United Kingdom. Epidemiol Infect 2007; 135:861-7
16. Slack MP. Invasive Haemophilus influenzae disease: The impact of Hib immunisation. J Med Microbiol 1995; 42:75-7
17. Hobson RP, Williams A, Rawal K, Pennington TH, Forbes KJ. Incidence and spread of Haemophilus influenzae on an Antarctic base determined using the polymerase chain reaction. Epidemiol Infect 1995; 114:93-103
18. van Ketel RJ, de Wever B, van Alphen L. Detection of Haemophilus influenzae in cerebrospinal fluids by polymerase chain reaction DNA amplification. J Med Microbiol 1990; 33:271-6
19. Falla TJ, Crook DW, Brophy LN, Maskell D, Kroll JS, Moxon ER. PCR for capsular typing of Haemophilus influenzae. J Clin Microbiol 1994; 32:2382-6
20. Gkentzi D, Slack MPE, Ladhani SN. The burden of nonencapsulated Haemophilus influenzae in children and potential for prevention. Curr Opinion Infect Dis 2012; 25:266-72
21. Jackson ML, Rose CE, Cohn A, et al. Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs. Emerg Infect Dis 2012; 18:13-20
22. McVernon J, Slack MP, Ramsay ME. Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: A comparison of two data sources. Epidemiol Infect 2006; 134:570-2
23. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl JMed 2008; 359:2355-65
24. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973-80
25. Ladhani S, Oeser C, Sheldon J, Ramsay M, Booy R, Heath PT. Immunoglobulin deficiency in children with Hib vaccine failure. Vaccine 2011; 29:9137-40
26. Ladhani S, Ramsay M, Flood J, et al. Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009. Euro Surveill 2012; 17. pii:20313
27. McVernon J, Ramsay M, McLean A. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2008; 136:800-12
28. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43:1387-94
29. Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8